GUTS
Fractyl Health, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$0.70
+1.35%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -4.6%
- EBIT
- +14.0%
- EPS
- +46.1%
- Free cash flow
- -0.1%
- Operating cash flow
- -1.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +51.7%
- EPS
- +58.9%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- -3.5%
- Net income
- —
- EPS
- +43.2%
- Free cash flow
- -35.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026